OncoMatch/Clinical Trials/NCT06580002
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Is NCT06580002 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Riluzole for breast cancer.
Treatment: Riluzole — This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Sarcoma
Gastric Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Renal Cell Carcinoma
Prostate Cancer
Urothelial Carcinoma
Testicular Germ Cell Tumor
Penile Carcinoma
Endometrial Cancer
Cervical Cancer
Prior therapy
Must have received: chemotherapy
Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
Must have received: anthracycline-containing chemotherapy
Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
Must have received: platinum-based chemotherapy
Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
Must have received: anticancer therapy
Non-breast cancer patients exposed to other anticancer therapies within the past 3 years
Lab requirements
Liver function
AST or ALT < 3x upper limit normal (ULN)
Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06580002 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and anthracycline-containing chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages